Spotlight
Money Desk
Obituaries
Classifieds
Families First
News
Weather
Specialists
Sports
Business
Opinion
Consumer
Health
Life
Out & About
Login
Recommended
Back to school guide: Buses, lunches, key dates
Recommended
UNC has a new chancellor. Why interim Lee Roberts got the permanent job.
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
Gold
Crude Oil
Local Stocks
WRALTechWire 30
WRALTechWire 30
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Arrowhead Pharma
(NQ:
ARWR
)
22.70
+0.04 (+0.18%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 16, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
687,944
Open
22.78
Bid (Size)
22.70 (3)
Ask (Size)
23.00 (5)
Prev. Close
22.66
Today's Range
22.39 - 23.04
52wk Range
20.67 - 39.83
Shares Outstanding
105,736,200
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Arrowhead Pharmaceuticals to Advance Two New RNAi-Based Obesity Candidates, ARO-INHBE and ARO-ALK7, Into Clinical Studies
August 14, 2024
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
ARWR Stock Earnings: Arrowhead Pharma Misses EPS for Q3 2024
August 08, 2024
ARWR stock results show that Arrowhead Pharma missed analyst estimates for earnings per share the third quarter of 2024.
Via
InvestorPlace
Performance
YTD
-26.80%
-26.80%
1 Month
-17.87%
-17.87%
3 Month
-8.54%
-8.54%
6 Month
-22.31%
-22.31%
1 Year
-19.67%
-19.67%
More News
Read More
Arrowhead Pharmaceuticals Reports Fiscal 2024 Third Quarter Results
August 08, 2024
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Arrowhead Pharmaceuticals Announces $500 Million Strategic Financing Facility with Sixth Street
August 08, 2024
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
July 29, 2024
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Arrowhead Pharmaceuticals to Webcast Fiscal 2024 Third Quarter Results
July 24, 2024
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
S&P Global To Rally More Than 13%? Here Are 10 Top Analyst Forecasts For Friday
July 05, 2024
Via
Benzinga
Topics
Stocks
Exposures
US Equities
What The Quest For New Cholesterol Treatments Means For Novartis, Merck — And Patients
July 05, 2024
Via
Investor's Business Daily
Have 20 Bucks? 7 Low-Priced Stocks That Could Double by 2025
June 28, 2024
Via
InvestorPlace
Arrowhead Pharmaceuticals to Advance RNAi-based Plozasiran into Phase 3 CAPITAN Cardiovascular Outcomes Trial
June 25, 2024
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Why Arrowhead Pharmaceuticals (ARWR) Stock Is Seeing Blue Skies
June 24, 2024
Via
Benzinga
Arrowhead Pharmaceuticals Presents Preclinical Data on New RNAi-Based Obesity Program ARO-INHBE
June 24, 2024
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
5 Biotech Stocks With Key Catalysts This Week: Merck, Intellia, Verona, And More
June 24, 2024
Via
Benzinga
Why Is Arrowhead Pharmaceuticals Stock Trading Higher On Monday?
June 03, 2024
Via
Benzinga
Stericycle, MarineMax, Agios Pharmaceuticals And Other Big Stocks Moving Higher On Monday
June 03, 2024
Via
Benzinga
Arrowhead Pharmaceuticals Reports Successful Topline Results for Plozasiran from the Pivotal Phase 3 PALISADE Study in Patients with Familial Chylomicronemia Syndrome
June 03, 2024
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Arrowhead Pharmaceuticals to Participate in Upcoming June 2024 Conferences
May 31, 2024
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Arrowhead Pharmaceuticals Presents New Phase 2 Data of Zodasiran in Patients with Mixed Hyperlipidemia
May 29, 2024
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Arrowhead Pharmaceuticals Presents New Phase 2 Data of Plozasiran in Patients with Mixed Hyperlipidemia
May 28, 2024
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Arrowhead Pharmaceuticals Presents New Clinical Data Showing ARO-RAGE Achieves High Level of Gene Knockdown in Patients with Asthma
May 20, 2024
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Double-Up Delights: 7 Stocks Poised to Soar 100% by 2025
May 14, 2024
Via
InvestorPlace
ARWR Stock Earnings: Arrowhead Pharma Misses EPS for Q2 2024
May 09, 2024
Via
InvestorPlace
Arrowhead Pharmaceuticals Reports Fiscal 2024 Second Quarter Results
May 09, 2024
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Why Diodes Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session
May 10, 2024
Via
Benzinga
Amgen Reports Better-Than-Expected Q1 Results, $50M Milestone Payment
May 02, 2024
Via
Benzinga
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.